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ABSTRACT
Objective Glutamate is the principal excitatory
neurotransmitter and is involved in normal brain function.
Cognitive impairment is common in multiple sclerosis
(MS), and understanding its mechanisms is crucial for
developing effective treatments. We used structural and
metabolic brain imaging to test two hypotheses: (i)
glutamate levels in grey matter regions are abnormal in
MS, and (ii) patients show a relationship between
glutamate concentration and memory performance.
Methods Eighteen patients with relapsing-remitting MS
and 17 healthy controls were cognitively assessed and
underwent 1H-magnetic resonance spectroscopy at 3 T to
assess glutamate levels in the hippocampus, thalamus,
cingulate and parietal cortices. Regression models
investigated the association between glutamate
concentration and memory performance independently of
magnetisation transfer ratio values and grey matter
lesions withint he same regions, and whole-brain grey
matter volume.
Results Patients had worse visual and verbal memory
than controls. A positive relationship between glutamate
levels in the hippocampal, thalamic and cingulate regions
and visuospatial memory was detected in patients, but
not in healthy controls.
Conclusions The relationship between memory and
glutamate concentration, which is unique to MS patients,
suggests the reliance of memory on glutamatergic systems
in MS.
INTRODUCTION
Cognitive impairment is common in multiple scler-
osis (MS), occurs at all stages of the disease and
greatly impacts on patients’ lives.1 Memory is fre-
quently affected and has been linked to both wide-
spread grey matter (GM) cortical thinning2 and
atrophy in speciﬁc GM regions, such as the hippo-
campus.3 MRI-derived GM atrophy may reﬂect
neuronal loss, demyelination or reduced synapse or
glial densities.4 Neuronal loss and demyelination
can be prominent features in the hippocampi of
MS patients.5 Demyelinated MS hippocampi also
show reductions in synaptic density and in the
neuronal proteins essential for axonal transport,
synaptic plasticity, glutamate neurotransmission,
glutamate homeostasis and memory, relative to nor-
mally myelinated hippocampi.6 Similarly, reduc-
tions in excitatory amino acid transporters, which
carry glutamate from the synaptic cleft to astro-
cytes, have been observed.7 These postmortem
ﬁndings implicate abnormal glutamate neurotrans-
mission in cognitive impairment in MS.
Current imaging techniques do not allow direct
measurement of glutamate neurotransmission
because several of its components are not detectable
in vivo, including the functioning of glutamate recep-
tors and transporters, glutamate–glutamine cycling
and synaptic activity. However, estimates of the total
concentration of glutamate (and its precursor glutam-
ine) can be obtained with in vivo MR spectroscopy
(MRS). Although the availability of the neurotrans-
mitter pool cannot be measured in vivo, the concen-
tration of glutamate inside the nerve terminal cells is
several thousand times higher than in the extracellu-
lar ﬂuid. MRS studies in patients with schizophrenia
have demonstrated reduced glutamate levels and
increased glutamine concentration in the medial pre-
frontal region,8 suggesting aberrant glutamatergic
processes in schizophrenia. In people with MS, MRS
studies have shown increased glutamate levels in
active lesions and normal-appearing white matter
(WM), suggesting possible mechanisms of glutamate-
mediated excitotoxicity, but normal levels in chronic
lesions, compared with controls.9 The effect of MS
on levels of glutamate in the GM remains unknown.
In this study, we address two hypotheses: (i) glu-
tamate levels in hippocampal, thalamic, cingulate
and parietal GM regions are abnormal in patients
with relapsing-remitting (RR) MS; (ii) there is an
association between glutamate levels in GM regions
and memory function. In particular, we predicted
that visuospatial memory would be related to glu-
tamate in these regions, given its links with the
right hippocampus,10 and previous links with thal-
amic integrity in people with MS.11 12 We also
investigated whether this association was independ-
ent of imaging measures derived from the same
areas, reﬂecting structural damage (such as demye-
lination and reduced axonal density).
MATERIALS AND METHODS
Subjects
Eighteen patients with a diagnosis of RRMS13 and
without a history of relapse or treatment with corti-
costeroids within the preceding 4 weeks were
recruited. Seventeen age-matched and gender-
matched healthy volunteers were also studied.
Matching was carried out at group level and not on
a case-by-case basis. Written informed consent was
obtained for participation in the study, which was
approved by our local ethics committee.
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Cognitive tests
Visuospatial learning and memory was assessed using the Paired
Associates Learning (PAL) test from the CANTAB (Cambridge
Cognition, Cambridge, UK). In this test, participants have to
remember the location of patterns presented in different areas of
the screen. The number of patterns increases over a series of
trials from two to eight patterns. Two age-scaled z-scores are pro-
duced based on standardised normative data: the number of
trials completed at the ﬁrst attempt and the total number of trials
needed to complete the test. To assess cognition generally, we
also assessed verbal learning and memory using list-learning from
the Adult Memory and Information Processing Battery (AMIPB)
and working memory with the digit-span from the Wechsler
Adult Intelligence Scale-III.14 Speed of information processing
was assessed using the oral version of the Symbol-Digit
Modalities Test (SDMT), for which z-scores were obtained with
reference to published norms.15 Executive function was mea-
sured using the Stroop colour-word interference test.16
Premorbid IQ was measured using the National Adult Reading
Test, and current IQ was measured with the two-subtest version
of the Wechsler Abbreviated Scale of Intelligence (vocabulary and
matrix reasoning). Levels of anxiety and depression were mea-
sured with the Hospital Anxiety and Depression Scale.17
Failure of a test (ie, PAL trials at ﬁrst attempt, PAL total trials,
AMIPB list learning, AMIPB delayed recall, SDMT, Stroop) was
deﬁned as a score at two or more SDs below the mean of the
controls. Patients with signiﬁcant cognitive impairment were
deﬁned as those showing failure on at least two tests.
MRI protocol and analysis
Imaging was performed on a 3 T Siemens Tim Trio scanner
with a 32-channel head coil.
Magnetisation Transfer (MT) imaging
Sagittal volumes were acquired at 1×1×1 mm3 (FOV
240×256×176 mm3; phase encoding direction superior/inferior;
GRAPPA acceleration factor 2). A slab selective 3D multiecho
FLASH sequence (repetition time (TR)=23.7 ms, echo time (TE)
=2.2 ms, ﬂip angle (α)=6°) was performed twice, with either pre-
dominantly PD-weighting (eight equally spaced echoes with a TE
difference of 2.5 ms) or MT-weighting (with an additional 4 ms
off-resonance Gaussian radiofrequency (RF) pulse (nominal
α=220°, offset frequency 2 kHz) before each excitation pulse, six
equally spaced echoes18). The multiecho data were averaged (for
the PD-weighted images, the ﬁrst six echoes only were averaged)
and the resulting MT-w (MTon) and PD-w (MToff) images were
coregistered to the T1-weighted volume prior to calculation of the
magnetisation transfer ratio (MTR) maps (MTR=MToff – MTon/
MToff). MTR maps were masked using the spectroscopic
volumes-of-interest (VOIs), and the mean MTR was calculated
within each VOI.
Single-voxel spectroscopy
A single-voxel PRESS with chemical selective saturation water sup-
pression was used (TR=6000 ms, TE=30 ms). The long TR was
chosen to minimise the potential effect of pathological T1 changes
on the acquired spectra. The dimensions and averages for the VOI
were as follows: (1) right hippocampus: dimensions
26×16×16 mm3, VOI volume=7.3 mL, 144 averages; (2) right
thalamus: dimensions 26×16×16 mm3, VOI volume=6.7 mL,
144 averages; (3) posterior cingulate cortex: dimensions
30×25×16 mm3, VOI volume=12 mL, 48 averages; and (4)
medial posterior parietal cortex: dimensions 25×25×25 mm3, VOI
volume=15.6 mL, 48 averages. Example placements of each VOI
can be seen in ﬁgure 1. A non-water-suppressed spectrum was also
acquired with the same parameters (two averages) to provide an
internal water reference to scale the measured metabolite signals.
The spectra were analysed using LCModel 6.1.19 LCModel was
used to estimate the concentrations of glutamate ([Glu]),
glutamate plus glutamine ([Glx]), total N-acetyl-aspartate and
N-acetyl-aspartate glutamate ([tNA]), choline-containing com-
pounds ([Cho]), creatine-plus-phosphocreatine ([tCr]) and
myo-Inositol ([mIns]), which were scaled using the water signal
from a non-water-suppressed spectrum. All spectra were checked
for quality. The right hippocampal spectrum was not acquired in
one patient, and the cingulate spectrum was not acquired in one
control due to time constraints. Four patients and two controls
had poor hippocampal spectra and two patients had poor thalamic
spectra, with signal to noise ratios (SNR) less than 10. These were
excluded from the analyses. Reanalysing data with all participants
included did not affect the pattern of results. Example spectra for
each VOI in a control participant can be seen in ﬁgure 1.
The GM, WM and cerebrospinal ﬂuid (CSF) masks obtained
by segmentation of the T1 scans were used to calculate the frac-
tional tissue content of each VOI. With these, it was possible to
estimate the water concentration within each VOI and estimate
the amplitude of the water signal in each VOI. We also used
literature-based values of T1 and T2 relaxation times of GM,
WM and CSF for each VOI, and the sequence parameters (TE
and TR), to correct the LCModel output for VOI water content
(see online supplementary information for further details).
Estimated metabolite concentrations thus corrected are reported
in ‘institutional units’ (iu).
Conventional imaging
Participants underwent axial T2-weighted imaging (turbo spin–
echo (TSE) with spatial resolution of 0.9×0.9×3 mm3,
TR=5760 ms, TE=101 ms), which was used to mark
T2-hyperintense lesions, and 3D T1-weighted imaging
(magnetisation-prepared rapid gradient echo with spatial reso-
lution of 0.9×0.9×0.9 mm3, inversion time (TI)=900 ms,
TR=1900 ms, TE=2.81 ms). Hypointense lesions on the
T1-weighted volume were marked and ﬁlled using the average
WM intensity20 before segmentation using the ‘new_segment’
function in SPM8 (http://www.ﬁl.ion.ucl.ac.uk/spm/software/
spm8), which reduces the impact of lesion-associated segmenta-
tion bias on GM and WM segmentations.20 Intracranial
volumes were deﬁned in each subject by ﬁrst using a maximum
likelihood algorithm to binarise the GM, WM and CSF tissue
volumes and then summing each of these volumes.
Double inversion recovery lesions
All subjects also underwent 3D double inversion recovery (DIR)
imaging (using an optimised long echo train TSE readout with
spatial resolution of 1.3×1.2×1.2 mm3, TR=10 000 ms,
TE=274 ms, TI=3000/510 ms). DIR lesions were marked for
each patient, following recent consensus recommendations.21 In
order to count the number of DIR lesions within each spectro-
scopic voxel, T1-weighted scans were rigidly registered to DIR
scans; the resulting transformation parameters were then
applied to the MRS voxels to transform them into DIR space.
Statistical analyses
Differences in cognitive performance and metabolite
concentrations between groups
Differences between all patients (and cognitively impaired (CI)
and cognitively preserved (CP) patients, see online supplementary
Muhlert N, et al. J Neurol Neurosurg Psychiatry 2014;85:834–840. doi:10.1136/jnnp-2013-306662 835
Multiple sclerosis
information) and controls in demographics, neuropsychological
test performance, MTR values in the spectroscopic regions and in
the GM or WM volume fractions in the VOIs were compared
using independent-sample t tests. Group differences in [Glu] (and
other metabolites) were initially tested using a repeated measures
multivariate analysis of variance (MANOVA) with factors of group
(patient vs control) and spectroscopic VOI (hippocampus, thal-
amus, cingulate and parietal cortices), therefore applying family-
wise correction for multiple comparisons. The repeated measures
MANOVA was used to examine group differences in metabolites
and interactions between groups and regions. When the
MANOVA showed signiﬁcant group differences across all four
Figure 1 Placement of MR spectroscopy (MRS) voxels (left) with their example MRS spectra (right) in the right hippocampus (A), parietal cortices
(B), right thalamus (C) and cingulate (D).
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VOIs, group differences were then tested in each VOI using inde-
pendent samples t tests. A signiﬁcance threshold of p<0.05 was
used throughout.
Association between cognitive performance and regional
glutamate levels in patients and controls
Associations between [Glu] and cognitive performance in all
patients were investigated using three linear regression models,
each with different independent variables. In the ﬁrst, the [Glu]
of each region was entered into the model as predictor, and
visuospatial memory as the outcome variable. The same analyses
were repeated in controls.
When a signiﬁcant association (or a trend towards signiﬁ-
cance) between [Glu] and cognitive test performance was found,
a second linear regression model was run, entering the [Glu] of
a speciﬁc VOI, the DIR GM lesions within the spectroscopic
VOI and the MTR value of the VOI, as predictors, and the cog-
nitive test performance as the dependent variable. This aimed at
identifying whether [Glu] was associated with memory perform-
ance independently from MTR and GM lesions. The partial
correlation coefﬁcients (PCCs), which give a measure of the
relative strengths of the independent associations between pre-
dictors and dependent variable, were reported when more than
one predictor was found to be signiﬁcant. Finally, the regression
analyses in which [Glu] signiﬁcantly predicted memory perform-
ance were repeated, including whole-brain GM volume fraction
as predictor, to assess whether GM volume mediated the effect.
All statistical analyses were carried out using the statistical
package for social scientists (SPSS) V.20.0. An α level of p<0.05
was used throughout, and signiﬁcance values less than 0.10
were considered trends.
To complete this study, the link between [Glu] and [tNA] and
between [tNA] and memory was assessed in patients; methods
and results for this section are described in the online supple-
mentary information.
RESULTS
Demographics, clinical and cognitive results
The demographic and clinical characteristics of all subject
groups are shown in table 1. Taken together, all patients showed
worse visuospatial memory than controls on the PAL test, with
fewer trials completed at the ﬁrst attempt (t=2.4, p<0.05) and
fewer trials completed overall (t=3.0, p<0.01) (table 1).
Patients also had worse verbal memory than controls, with
worse learning of the list (t=3.3, p<0.01), fewer words recalled
after distraction (t=3.2, p<0.01) and fewer words recalled after
a 30 min delay (t=2.2, p<0.05). Patients had slower processing
speed than controls on the SDMT (t=4.7, p<0.001) and were
worse on the Stroop task, suggesting impaired executive func-
tion (t=−4.0, p<0.01) (table 1). In contrast, patients and con-
trols did not differ on working memory (t=1.7, p=0.10) (table
1). Additionally, patients did not differ from controls in their
age, their premorbid IQ or their current IQ; the two groups
showed no signiﬁcant differences in levels of anxiety or depres-
sion (table 1).
Glutamate levels in GM regions are lower in MS patients
than controls
The MANOVA analysis showed that all patients together had
signiﬁcantly lower [Glu] (and [Glx]) in GM regions than con-
trols ([Glu]: Pillai’s trace=0.5, F=5.684, p<0.01; [Glx]: Pillai’s
trace=0.4, F=3.53, p<0.05). There was no signiﬁcant inter-
action between group and region for [Glu] (p=0.18) or [Glx]
(p=0.56). Subsequent univariate analyses in each individual
VOI revealed that the patient group had signiﬁcantly lower
[Glu] (and [Glx]) in the cingulate and parietal cortices
(all p<0.01), and a trend towards lower [Glu] in the right
hippocampus (p=0.10) when compared with controls (table 2,
Table 1 Mean (SD) demographics and cognitive performance for
patients and controls
Demographic and clinical
characteristics Controls Patients
N 17 18
Age (SD, median, range) 39.7 (11.1, 40.0, 29–60) 43.5 (8.5, 44.0, 31–57)
Gender (M:F) 11:6 12:6
EDSS (median (range)) – 3.25 (1.0–6.5)
Premorbid IQ 108.6 (11.7) 105.2 (13.4)
Current IQ 112.6 (16.8) 110.4 (12.9)
Anxiety 5.3 (2.8) 5.4 (3.9)
Depression 2.7 (3.5) 3.9 (3.2)
Paired associate learning
Trials at first attempt, z-score 0.2 (1.3) −0.7 (1.1)*
Total trials, z-score 0.2 (1.0) −0.8 (0.9)**
List learning
Learning (total words) 57.7 (9.0) 47.2 (9.3)**
Recall after distraction
(words recalled)
12.2 (2.2) 9.2 (3.1)**
30 min delayed recall
(words recalled)
11.8 (2.4) 9.7 (3.2)*
Digit span (total score) 18.4 (3.1) 16.6 (3.3)
Stroop (seconds to complete) 101.7 (12.3) 150.5 (49.2)**
SDMT, z-score 0.9 (0.8) −0.9 (1.2)***
Asterisks indicate significantly different results between patients and controls using
independent samples t tests (*p<0.05, **p<0.01, ***p<0.001).
EDSS, expanded disability status scale; SDMT, symbol-digit modalities test.
Table 2 Mean (SD) glutamate ([Glu]) and glutamate and
glutamine ([Glx]) concentration estimates in institutional units for
patients and controls
Controls Patients
Hippocampus
Glu 4.57 (1.2) 3.94 (1.1)
Glu %SD 8.85 (2.5) 9.85 (3.8)
Glx 5.19 (1.5) 4.48 (1.5)
Glx %SD 10.36 (3.4) 11.23 (4.0)
Thalamus
Glu 4.99 (1.5) 4.79 (2.1)
Glu %SD 12.35 (3.60) 11.47 (3.5)
Glx 5.84 (2.4) 6.05 (3.9)
Glx %SD 12.56 (3.8) 13.35 (4.0)
Cingulate cortex
Glu 7.60 (0.6) 6.24 (1.3)*
Glu %SD 6.12 (0.8) 6.72 (1.4)
Glx 8.31 (0.8) 6.94 (1.5)*
Glx %SD 6.71 (1.3) 7.22 (1.3)
Parietal cortex
Glu 7.44 (0.7) 6.30 (1.1)*
Glu %SD 5.35 (0.9) 5.89 (1.5)
Glx 8.49 (0.8) 7.21 (1.2)*
Glx %SD 5.58 (0.7) 6.39 (1.6)
*p<0.01 for patients versus controls comparison.
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ﬁgure 2). To complete the study, the differences between all
patients and controls in [tNA] and [tCr] were examined and
results are reported in the online supplementary information.
On the other measures of structural damage calculated within
the spectroscopic voxels, all patients together showed signiﬁ-
cantly lower MTR than controls in the thalamic, cingulate and
parietal regions, but no group differences in GM or WM
volume fractions were observed (table 3).
Associations between imaging measures and cognitive
impairment
Memory was signiﬁcantly associated with [Glu] in the hippo-
campus, thalamus and cingulate VOIs in all patients, as reported
below (ﬁgure 2). Statistically signiﬁcant results in patients did
not change after correcting the models for whole-brain GM
volume fraction. Healthy controls did not show signiﬁcant asso-
ciations between memory and [Glu] in any of the GM regions
(ﬁgure 2).
Hippocampus
PAL trials completed at ﬁrst attempt were signiﬁcantly predicted
by hippocampal [Glu] (coeff.=0.69, 95% CI 0.20 to 1.09,
p=0.008, PCC=0.69). Entering hippocampal MTR and hippo-
campal DIR lesions as predictors revealed that only hippocam-
pal [Glu] showed a trend for predicting PAL trials at ﬁrst
attempt (coeff.=0.60, 95% CI −0.01 to 1.13, p=0.054,
PCC=0.59).
There was a trend towards a signiﬁcant association between
PAL total trials and hippocampal [Glu] (coeff.=0.55, 95%
CI −0.01 to 0.64, p=0.051, PCC=0.55). This trend became
signiﬁcant after correcting for hippocampal MTR and hippo-
campal DIR lesions (coeff.=0.71, 95% CI 0.01 to 0.82,
p=0.049, PCC=0.60).
Thalamus
There was a trend towards a signiﬁcant association between PAL
trials at ﬁrst attempt and thalamic [Glu] (coeff.=0.24, 95% CI
−0.04 to 0.52, p=0.088). Entering thalamic MTR and thalamic
DIR lesions to the model revealed that thalamic [Glu] and thal-
amic DIR lesions signiﬁcantly predicted PAL trials at ﬁrst
attempt ([Glu]: coeff.=0.53, 95% CI 0.09 to 0.49, p=0.009,
PCC=0.70; DIR lesions: coeff.=−0.68, 95% CI −1.09 to
−0.26, p=0.004, PCC=−0.71).
PAL total trials were not associated with thalamic [Glu].
Cingulate cortex
PAL trials at ﬁrst attempt were signiﬁcantly predicted by cingu-
late [Glu] (coeff.=0.54, 95% CI 0.07 to 0.80, p=0.022).
Adding cingulate MTR and cingulate DIR lesions revealed that
cingulate [Glu] and cingulate DIR lesions signiﬁcantly predicted
PAL at ﬁrst trial ([Glu]: coeff.=0.50, 95% CI 0.02 to 0.79,
p=0.038, PCC=0.52; DIR lesions: coeff.=−0.46, 95% CI
−0.35 to −0.01, p=0.037, PCC=−0.52).
PAL total trials were not associated with cingulate [Glu].
Parietal cortex
Parietal [Glu] did not predict memory.
Correcting for GM and WM fraction
Repeating the regression models after including GM fraction
and WM fraction did not change the pattern of results.
DISCUSSION
We provide support for (i) MS-related modiﬁcations of glutam-
ate levels in speciﬁc GM regions and (ii) positive correlations
between glutamate levels and visuospatial memory performance
in MS. The same associations are not detected in healthy con-
trols. We discuss these two ﬁndings in turn.
When all patients were grouped together, glutamate was sig-
niﬁcantly lower in patients than healthy controls in the parietal
and cingulate regions, and there was a trend towards lower glu-
tamate in the right hippocampus in patients. Glutamate–glutam-
ine levels were similarly reduced in patients compared with
controls, indicating an overall reduction in glutamatergic activity,
since glutamine is the precursor of glutamate. MRS quantiﬁcation
of glutamate concentrations does not allow us to draw ﬁrm con-
clusions about the mechanisms underlying the observed reduc-
tions, as many of the components of glutamate-mediated
neurotransmission may be implicated and these are not
Figure 2 Three scatter plots showing the associations and line of
best ﬁt between memory function and [Glu] in the hippocampus (A),
thalamus (B) and cingulate (C) for patients (black diamonds and solid
line) and controls (open squares and dotted line).
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detectable in vivo. Glutamate is much more abundant inside cells
than in the extracellular space, and its highest concentrations are
found in the synaptic vesicles. Therefore, a possible interpret-
ation is that reduced synapses and neuronal–axonal degeneration,
which have been described in histological analyses of MS
brains,22 may be relevant for determining lower glutamate levels.
Along the same lines, reduced glutamate, possibly associated with
shrinkage/neuronal loss, has been described during the ageing
process23 and in schizophrenia.8 Finally, the observed (and posi-
tive) correlations between glutamate and tNA in the hippocam-
pal, cingulate and parietal regions suggest that reduced neuronal
integrity and/or metabolism, reﬂected by reduced tNA,24 may
underlie the same pathological processes reﬂected by reduced
glutamate levels.
Considering the thalamic and hippocampal regions, no group
differences in glutamate and glutamate–glutamine were found in
the thalamic voxel, and a trend towards statistical signiﬁcance
was detected in the hippocampus. This may reﬂect the unique
tissue microstructure of the thalamus when compared with cor-
tical regions (the thalamus is a striated GM and WM structure)
and be related to the greater technical challenge of segmenting
the thalamic region with SPM8,25 and of acquiring spectra in
the thalamus and, to a lesser extent, the hippocampus.26 Yet,
whereas previous studies carried out at lower ﬁeld strengths
(1.5 T) have generally considered glutamate and glutamine
together, we were able to identify the glutamate resonance with
an acceptable level of conﬁdence. We also improved the accur-
acy of our metabolite concentrations by adjusting them for
water content of GM, WM and CSF and for regional T1 and
T2 values.
When looking at the associations between glutamate concen-
trations and cognitive tests, we found that, in patients, visuo-
spatial memory was signiﬁcantly associated with hippocampal
glutamate independently of MTR and DIR GM lesions within
the same region. Additionally, in patients, visuospatial memory
was more strongly predicted by cingulate glutamate than by DIR
lesions within the cingulate. Worse visuospatial memory in
patients was also predicted by lower glutamate in the thalamic
region, although thalamic DIR lesions were equally (and
independently) predictive. All these associations remained sig-
niﬁcant after adjusting for whole-brain GM volume fraction.
Since MTR is sensitive to cortical demyelination,27 while DIR
lesions reﬂect focal areas of demyelination,28 these ﬁndings
suggest that the association between memory and glutamate
levels may not depend on cortical demyelination or overall GM
atrophy. Overall, these ﬁndings suggest that (i) glutamate levels
in these GM regions reﬂect processes that are linked with
memory function in MS; these processes are unlikely to occur
in the general population given that these correlations were not
found in healthy controls. (ii) DIR GM lesions in the thalamic
region may also affect memory function, which conﬁrms previ-
ously published reports on the association between thalamic
lesions and atrophy and memory function in MS.11
In schizophrenia, reduced cortical glutamate in frontal regions
is known to be associated with impaired cognition,29 and cogni-
tion is impaired in healthy humans given NMDA antagonists.30
Both CI and CP patients showed similar reductions in glutamate
levels in the parietal and cingulate GM regions when compared
with controls (overall differences were between 15% and 22%,
see online supplementary information), suggesting that glutam-
ate levels reﬂect MS-related pathological processes, rather than a
dysfunction that speciﬁcally mediates cognitive impairment.
Future work will aim to examine whether people with MS also
show changes in glutamate levels in other GM regions that are
known to contribute to cognitive function, such as the frontal
regions and subcortical GM nuclei, and whether such changes
help to explain cognitive impairment.
In contrast to glutamate, tNA did not signiﬁcantly predict
memory. This study did not aim to assess the comparative pre-
dictive values of glutamate and tNA, and given their strong cor-
relation, it would have been underpowered to do so.
Our study has some unavoidable limitations. First, because of
the cuboidal shape of the spectroscopic VOIs and the linear
relation between VOI volume and spectroscopic SNR, in order
to achieve reliable estimates of metabolite concentrations in rea-
sonable acquisition times, it was necessary to have VOIs that
encompassed the GM of interest rather than being completely
contained within it. Therefore, inevitably these VOIs included
Table 3 T2 lesion load and total and regional DIR GM lesions of patients, and MTR values within the spectroscopic voxels of patients and
controls
Controls Patients
T2 lesion load (mean (SD)) – 7.05 mL (7.60)
DIR lesions (median (range))
Total grey matter lesions – 22 lesions (range 6–275)
Hippocampal lesions in the right hippocampal spectroscopic VOI – 0.5 lesions (range 0–3)
Thalamic lesions in the right thalamic VOI – 0 lesions (range 0–2)
Grey matter lesions in the cingulate cortex VOI – 0 lesions (range 0–12)
Grey matter lesions in the post. parietal VOI – 1 lesion (range 0–6)
Total GM lesions in each structure on DIR (median[range])
Right hippocampal lesions 0.5 lesions (range 0–3)
Right thalamic lesions 0 lesions (range 0–2)
GM fraction (mean (SD)) 0.45 (0.04) 0.42 (0.02)*
MTR (mean (SD))
MTR in the right hippocampal VOI 33.1 (2.0) 31.1 (4.4)
MTR in the right thalamic VOI 30.8 (1.5) 29.1 (2.8)*
MTR in the cingulate cortex VOI 30.9 (1.1) 28.6 (2.7)*
MTR in the posterior parietal VOI 37.9 (0.9) 35.3 (2.5)*
Note that the number of DIR lesions in the patients’ hippocampus and thalamus was similar to those seen in the spectroscopic hippocampal and thalamic voxels.
*p<0.05.
DIR, double inversion recovery; GM, grey matter; MTR, magnetisation transfer ratio; VOI, spectroscopic volume of interest; WM, white matter.
Muhlert N, et al. J Neurol Neurosurg Psychiatry 2014;85:834–840. doi:10.1136/jnnp-2013-306662 839
Multiple sclerosis
some of the WM surrounding the regions of interest. However,
patients and controls showed no differences in the GM and
WM volume fractions, the regressions were generally unaffected
after accounting for GM and WM fractions and fractions were
used to adjust the glutamate concentration for water content of
both tissue types. Additionally, the relationship between glutam-
ate levels and cognitive performance did not change after cor-
recting for whole-brain GM volume fraction. Second, 16
regressions were performed without formal correction for mul-
tiple comparisons. This can be justiﬁed by the fact that this is a
hypothesis-driven rather than an exploratory study, making the
need for multiple comparison corrections less relevant.31 In this
case, controlling for type II errors is as important as controlling
for type I errors. Finally, while the study was powered to assess
differences in glutamate between patients and controls, it was
not powered to assess differences between CI and CP patients.
These data however answer an interesting posthoc question that
can be explored in future work.
CONCLUSION
Using a MRS protocol optimised for glutamate detection, but
widely available at 3 T, this study provides the ﬁrst evidence that
MS affects glutamate levels in GM and that worse visuospatial
memory is linked to lower glutamate in the hippocampal, thal-
amic and cingulate regions in RRMS patients. As in other
neuropsychiatric diseases,29 the discovery of a link between glu-
tamate abnormalities in the GM of MS patients and reduced
memory performance may lead to new treatment approaches
that speciﬁcally modulate this neurotransmitter.
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